BioSpace News Archive

A Korean molecular diagnostic company, Gencurix, Inc., has announced that they have received U.S. Food and Drug Administration (FDA)'s Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test.

inContext.ai, a developer of healthcare-centric information extraction software and AI-powered clinical applications, announced an award of $225K in National Science Foundation funding.

Smart pump programming will allow HCA Capital’s Medfusion® 4000 pumps to be programmed based on the clinician order, reducing programming errors.

The George Washington University Medical Faculty Associates, one of the largest physician-led practice groups in the Washington, DC region, an affiliate of the George Washington University, and nThrive, an independent Patient-to-Payment℠ revenue cycle solutions company, announced a new agreement to optimize revenue cycle operations and improve the patient experience at the MFA.

Multidisciplinary program treats transgender patients with a comprehensive care team, promotes research and advocacy in gender affirming healthcare

Partnership Brings Together RapidAI’s Market-Leading Cerebrovascular Imaging Analysis with Life Image’s Extensive Global Network of Trauma Hospitals and Referral Sites

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,187,500 shares of the Company’s common stock, at a purchase price of $8.00 per share, in a registered direct offering. The closing of the offering is expected to occur on or about June 26, 2020, subject to the satisfaction of customary

Signing of two “PGE” loans and innovation loan for €3.2 million and receipt of € 2.3 million in grants from Bpifrance within the PSPC MIVANA R&D project. Appointment of two experienced and successful Healthtech entrepreneurs as Board Members: Jean-François Le Bigot and Benoît Adelus AIX-EN-PROVENCE, France--( BUSINESS WIRE )-- Affluent Medical is a French MedT

Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS ® (ravulizumab-cwvz) Met Primary Endpoint - Ongoing Phase 3 study demonstrated PK non-inferiority of ULTOMIRIS SC versus ULTOMIRIS IV at Day 71 - - Preliminary safety data consistent with the known safety profile of ULTOMIRIS -

Genova Diagnostics introduces a new collect-at-home nutritional test to help support telemedicine practices and provide clinicians a more comprehensive set of options without a blood draw.